New Veeva app connects medtech firms with KOLs

Veeva Systems has launched its latest cloud-based data application for the life sciences sector, aimed at clinical teams in the medical devices and diagnostics sector.

The new app – called Veeva Link Medtech – will help medical affairs, commercial, and key account management teams in medtech companies identify and engage with key opinion leaders (KOLs), said the company in a statement.

The app is part of Veeva’s Link family of connected data apps for identifying experts who can help with a new launch, for example, as well as finding engagement opportunities, and strategic planning.

The platform – which is now available globally, according to Veeva – combines intelligent software automation with human curation to ensure accuracy and depth across a growing number of functions, including sales, medical, marketing, and clinical. It can keep track of experts and their scientific activities in real-time.

That includes expert tweets, research findings, and collaborations, which are aggregated in one place, plus thousands of local and national congresses and associations around the world.

“We are breaking new ground in how we use data to help the industry improve performance by empowering field teams with timely, accurate information about their most important customers,” said Juliane Ray, vice president of commercial strategy for Veeva MedTech.

“We’re proud to help medtech companies build relationships with the industry’s most influential KOLs to improve patient journeys.”

Link is a relatively new arm of Veeva’s portfolio that has seen a string of launches in the last couple of years. Those include a Scientific Awareness module to help medical teams with product strategy, Key People to keep track of experts across different therapeutic areas, Key Accounts for intelligence on major health systems, Medical Insights for information-sharing within organisations, and the workflow app Link+.

The business is part of the company’s commercial solutions arm, which is growing fast and expected to account for around $972 million of an estimated $2.35 billion in revenues for the current fiscal year.

It has seen strong growth in the last few years as the life sciences industry has digitised its commercial business model, with a shift towards moving operations into the cloud and stripping out legacy, fragmented IT systems.